320 studies found for:    "Alkylating Agents" | Studies updated in the last 30 days
Show Display Options
Rank Status Study
1 Active, not recruiting Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor
Conditions: Sarcoma;   Desmoplastic Small Round Cell Tumor (DSRCT)
Intervention: Drug: irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator
2 Recruiting Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cisplatin;   Radiation: Stereotactic Body Radiation Therapy (SBRT)
3 Recruiting Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma
Condition: Newly Diagnosed Ewing Sarcoma
Interventions: Drug: Cyclophosphamide;   Device: Doxorubicin;   Drug: Vincristine;   Device: Ifosfamide;   Drug: Etoposide;   Procedure: Surgery;   Radiation: Radiation Therapy*;   Drug: Temozolomide;   Drug: Irinotecan
4 Recruiting ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Conditions: Glioblastoma;   Gliosarcoma
Interventions: Drug: ERC1671;   Drug: GM-CSF;   Drug: Cyclophosphamide;   Drug: Oral Control (Sucrose pill);   Drug: Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%));   Drug: Bevacizumab
5 Recruiting A Pharmacokinetic Study of Melphalan in Children
Condition: Hematopoietic Stem Cell Transplantation
Intervention: Drug: Melphalan
6 Not yet recruiting ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia
Condition: Aplastic Anemia
Interventions: Drug: Rabbit ATG, (Genzyme);   Drug: Cy;   Drug: CsA;   Biological: Cord blood
7 Recruiting The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia
Condition: Waldenström Macroglobulinemia
Interventions: Drug: Bortezomib;   Drug: Rituximab
8 Recruiting Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme
Condition: Glioblastoma Multiforme
Interventions: Biological: anti-EGFRvIII CAR T cells;   Drug: cyclophosphamide;   Drug: Fludarabine
9 Not yet recruiting Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI
Condition: Glioblastoma
Interventions: Radiation: Avastin;   Radiation: Lomustine;   Radiation: Temozolomide;   Device: MRI;   Device: MRS;   Device: DSC
10 Recruiting R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis
Condition: Diffuse Large B-Cell Lymphoma
Interventions: Drug: R-DA-EPOCH-21;   Drug: R-DA-EPOCH-21 + auto-SCT;   Drug: R-mNHL-BFM-90;   Drug: R-mNHL-BFM-90 + auto-SCT
11 Recruiting Standard Chemotherapy Followed by Capecitabine as Prolonged Postoperative Adjuvant Treatment for Breast Cancer
Condition: Breast Cancer
Interventions: Drug: TA or TAC;   Drug: X
12 Recruiting Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Interventions: Drug: Metronomic cyclophosphamide;   Drug: Interferon-alpha
13 Completed DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Docetaxel, Doxorubicin;   Drug: Docetaxel, Doxorubicin, Cyclophosphamide
14 Recruiting BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Busulfan;   Drug: Etoposide;   Drug: Bendamustine
15 Not yet recruiting A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer
Condition: Ovarian Cancer
Interventions: Drug: Talazoparib;   Drug: Temozolomide
16 Not yet recruiting NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia
Conditions: Severe Aplastic Anemia;   Aplastic Anemia;   Bone Marrow Failure
Interventions: Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
17 Not yet recruiting A Clinical Trial on Whole-brain Radiotherapy With Temozolomide Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain Metastases
Conditions: Brain Metastasis;   Radiation Therapy Complication
Interventions: Drug: TMZ;   Radiation: WBRT with avoidance of hippocampus;   Radiation: WBRT without avoidance of hippocampus
18 Not yet recruiting Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Conditions: Functional Pancreatic Neuroendocrine Tumor;   Malignant Somatostatinoma;   Merkel Cell Carcinoma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Carcinoid Tumor;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2A;   Multiple Endocrine Neoplasia Type 2B;   Neuroendocrine Neoplasm;   Non-Functional Pancreatic Neuroendocrine Tumor;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Adrenal Gland Pheochromocytoma;   Recurrent Merkel Cell Carcinoma;   Somatostatin-Producing Neuroendocrine Tumor;   Stage III Adrenal Cortex Carcinoma;   Stage III Thyroid Gland Medullary Carcinoma;   Stage IIIA Merkel Cell Carcinoma;   Stage IIIB Merkel Cell Carcinoma;   Stage IV Adrenal Cortex Carcinoma;   Stage IV Merkel Cell Carcinoma;   Stage IVA Thyroid Gland Medullary Carcinoma;   Stage IVB Thyroid Gland Medullary Carcinoma;   Stage IVC Thyroid Gland Medullary Carcinoma;   Thymic Carcinoid Tumor;   VIP-Producing Neuroendocrine Tumor;   Well Differentiated Adrenal Cortex Carcinoma;   Zollinger Ellison Syndrome
Interventions: Drug: Capecitabine;   Drug: Temozolomide;   Drug: Veliparib;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
19 Not yet recruiting Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Condition: CD70 Expressing Cancers
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin;   Biological: Anti-hCD70 CAR PBL
20 Not yet recruiting Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia
Condition: Severe Aplastic Anemia
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Rabbit ATG

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years